All In Biotech

Drug Trial Radar · NCT00642941

A Study of R1507 in Participants With Recurrent or Refractory Sarcoma

A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.

Last checked: Nov 20, 2026Latest source record: Feb 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

317

Actual

Start

Dec 18, 2007

Primary completion

Feb 19, 2014

Study completion Feb 19, 2014

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Sarcoma Alliance for Research through Collaboration
First posted
Mar 25, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study was primarily designed to determine objective response, progression-free survival (PFS), and the safety and tolerability of R1507 in participants with recurrent or refractory Ewing's sarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma and other sarcomas including alveolar soft part sarcoma, desmoplastic small round cell tumor, extraskeletal myxoid chondrosarcoma, clear cell sarcoma, and myxoid liposarcoma.

Conditions

  • Sarcoma

Interventions

  • RG1507Drug

    Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Complete or Partial Response, According to World Health Organization (WHO) Criteria in Cohorts 2 to 8Time frame: Baseline up to 6 years (assessed at baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression)
  2. Progression-Free Survival (PFS) Rate According to WHO Response Criteria at 18 Weeks From Start of R2607 Treatment in Cohort 1Time frame: Baseline up to 18 weeks (assessed at baseline, every 6 weeks until disease progression)
  3. Percentage of Participants With Adverse Events (AEs) in Cohort 1 and 2Time frame: Baseline up to 6 years

Locations

41 sites in 11 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • UCLA School Of Medicine Mattel's Children's Hospital At UCLA; Division Of Hematology-Oncology

    Los Angeles, California

  • Sarcoma Oncology Center

    Santa Monica, California

  • Stanford Comprehensive Cancer Center

    Stanford, California

  • Washington Cancer Institute; Washington Hospital Center

    Washington D.C., District of Columbia

  • Kootenai Medical Center

    Coeur d'Alene, Idaho

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • NIH/NCI

    Bethesda, Maryland

  • Massachusetts General Hospital; Dana Farber Partnes Cancer Center

    Boston, Massachusetts

  • Dana Farber Partners Can Ctr

    Boston, Massachusetts

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan

  • Nebraska Methodist Hospital; Onc Hem West

    Omaha, Nebraska

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Albert Einstein College of Medical Pediatrics; Department of Pediatrics

    The Bronx, New York

  • Carolinas Hematology Oncology Associates; Investigational Drug Services - Pharmacy

    Charlotte, North Carolina

  • Oregon Health and Science University Cancer Institute

    Portland, Oregon

  • Pennsylvania Oncology Hema Asc

    Philadelphia, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Texas Children's Cancer Center; Baylor College of Medicine

    Houston, Texas

  • University of Texas M.D. Anderson Cancer Center

    Houston, Texas

  • Huntsman Cancer Institute; Orthopedic Center

    Salt Lake City, Utah

  • Peter Maccallum Cancer Institute; Medical Oncology

    Melbourne, Victoria, Australia

  • BCCA-Vancouver Cancer Centre

    Vancouver, British Columbia, Canada

  • Institut Bergonie; Oncologie

    Bordeaux, France

  • Centre Oscar Lambret; Chir Cancerologie General

    Lille, France

  • Centre Leon Berard; Departement Oncologie Medicale

    Lyon, France

  • Institut Curie; Oncologie Medicale

    Paris, France

  • Institut Gustave Roussy; Service Pediatrique

    Villejuif, France

  • HELIOS Klinikum Bad Saarow; Klinik für Innere Medizin III

    Bad Saarow, Germany

  • Uniklinik Mannheim; Sektion Chirurgische Onkologie & Thoraxchirurgie

    Mannheim, Germany

  • University Hospital Tübingen

    Tübingen, Germany

  • Istituti Ortopedici Rizzoli

    Bologna, Emilia-Romagna, Italy

  • Istituto Nazionale Tumori, Sarcoma Unit

    Milan, Lombardy, Italy

  • Erasmus Mc - Daniel Den Hoed Kliniek; Medical Oncology

    Rotterdam, Netherlands

  • Norwegian Radium Hospital

    Oslo, Norway

  • Hospital Sant Joan De Deu

    Esplugues de Llobregas, Barcelona, Spain

  • Skånes University Hospital, Skånes Department of Onclology

    Lund, Sweden

  • UCL Hospital NHS Trust

    London, United Kingdom

  • Royal Marsden Hospital; Dept of Med-Onc

    London, United Kingdom

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.